Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan 31;13(1):1-5.
doi: 10.21037/tcr-23-577. Epub 2024 Jan 29.

Can we successfully define and target BRCA-like breast cancers?

Nathalie LeVasseur  1   2 , Karen A Gelmon  1   2
Affiliations
Editorial

Can we successfully define and target BRCA-like breast cancers?

Nathalie LeVasseur et al. Transl Cancer Res. .
No abstract available

Keywords: BRCA-like; Poly (ADP-ribose) polymerase (PARP); biomarker; homologous recombination deficiency (HRD); veliparib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-577/coif). N.L. discloses receiving funds for participating in Advisory boards with the following: Astra Zeneca, Eli Lilly, Gilead, Merck, Knight Therapeutics, Novartis, Pfizer, Roche, Seagen, and TerSera, and receiving research funds to their institution from the following: Abbvie, Avon Foundation for Women, BC Cancer Foundation, CCS, CIHR, Eli Lilly, Exact Sciences, Gilead, and Michael Smith Health Research. K.A.G. declares that she receives research grants with funds to her institution from AstraZeneca, Pfizer and BMS, and payment or honoraria for Speakers event 2023 from Astra Zeneca. She also participates on the Advisory Board of Eli Lilly, Gilead, Merck, Novartis, Seagen and Testara, Advisory board and DMC of Astra Zeneca and Pfizer, and DMC of City of Hope. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Distribution of patients in the biomarker groups and proportion assigned to the BRCA-like phenotype based on the predefined qualifying markers (8). Germline testing was the first step for group allocation. If no germline mutation was identified, patients went on to have additional biomarker testing which comprised four predefined markers in rank order of priority, as listed from left to right. A positive result in any of these resulted in assignment to the BRCA-like phenotype. Those who underwent additional biomarker testing and could not be classified in the BRCA or non-BRCA phenotypes, comprising 22.8% of the overall study population, are shown in the right panel of this figure. *, total exceeds 100% as all 8 patients with somatic BRCA mutations had been classified in the BRCA-like phenotype by genomic instability score. HRR, homologous recombination repair.
See this image and copyright information in PMC

Comment on

References

    1. Engel C, Rhiem K, Hahnen E, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer 2018;18:265. 10.1186/s12885-018-4029-y - DOI - PMC - PubMed
    1. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018;379:753-63. 10.1056/NEJMoa1802905 - DOI - PMC - PubMed
    1. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017;377:523-33. 10.1056/NEJMoa1706450 - DOI - PubMed
    1. Diéras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:1269-82. 10.1016/S1470-2045(20)30447-2 - DOI - PubMed
    1. Stewart MD, Merino Vega D, Arend RC, et al. Homologous Recombination Deficiency: Concepts, Definitions, and Assays. Oncologist 2022;27:167-74. 10.1093/oncolo/oyab053 - DOI - PMC - PubMed